TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10912657

Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 8803529

Group type: EXPERIMENTAL
Intervention: Ursodiol (600 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1538234

Group type: EXPERIMENTAL
Intervention: CT scanning for TIA
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: CT scanning for RIND
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: CT scanning for minor stroke
Number of subjects: 2082
Study: 6704005

Group type: EXPERIMENTAL
Intervention: Group 1: 100 spots over 360 degrees
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group 2: 50 spots over 180 degrees
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group 3: 50 spots over 360 degrees
Number of subjects: 45
Study: 30790160

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 27998700

Group type: EXPERIMENTAL
Intervention: Section 8 voucher to move to lower poverty neighborhoods
Number of subjects: 2829

Group type: COMPARATOR
Intervention: Control group (public housing)
Number of subjects: 2829
Study: 25083614

Group type: EXPERIMENTAL
Intervention: Single-dose rabbit antithymocyte globulin (SD-rATG) 6 mg/kg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Divided-dose rabbit antithymocyte globulin (divided-dose-rATG)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: SD-rATG
Number of subjects: 180

Group type: COMPARATOR
Intervention: SD-rATG and divided-dose-rATG
Number of subjects: 180
Study: 23188543

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 90
Study: 21540604

Group type: EXPERIMENTAL
Intervention: Tube group (TG)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Intra-operative tube group (ITG)
Number of subjects: 161

Group type: COMPARATOR
Intervention: No-tube group (NTG)
Number of subjects: 161
Study: 18310205

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm, weaned to 2 ppm)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 100
Study: 17077928

Group type: EXPERIMENTAL
Intervention: Selective head cooling with an insulated ice cap, aiming for a target rectal temperature of 35-35.5 degrees C and a target scalp temperature of 10-28 degrees C.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cooling technique using an insulated ice cap with additional insulation.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cooling technique with lower core temperatures of 33-34 degrees C.
Number of subjects: 20
Study: 15226338

Group type: EXPERIMENTAL
Intervention: Adult oncology informed consent process
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Pediatric oncology informed consent process
Number of subjects: 219
Study: 10694138

Group type: EXPERIMENTAL
Intervention: Propranolol plus caffeine (Pr+C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Propranolol (Pr)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 15
Study: 9186381

Group type: EXPERIMENTAL
Intervention: Aspirin (160 mg/day) started within 48 hours of onset of suspected acute ischaemic stroke and continued for up to 4 weeks
Number of subjects: 21106

Group type: EXPERIMENTAL
Intervention: Aspirin (160 mg/day)
Number of subjects: 21106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21106
Study: 1402726

Group type: EXPERIMENTAL
Intervention: CPCP office system intervention
Number of subjects: 50
Study: 3880687

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice a day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg twice a day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Labetalol (400 mg twice a day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg twice a day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30209858

Group type: EXPERIMENTAL
Intervention: Ever-drinking
Number of subjects: 466434

Group type: COMPARATOR
Intervention: Genetically assessed unit of alcohol/week
Number of subjects: 466434
Study: 29982097

Group type: EXPERIMENTAL
Intervention: Handgrip exercise (25 repetitions, 3 times daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Handgrip exercise (25 repetitions, 6 times daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (gentle limb exercise with no frequency and intensity requirements)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 27509600

Group type: COMPARATOR
Intervention: Control group (acupuncture method of 'Xingnao Kaiqiao' and oral administration of nifedipine)
Number of subjects: 68
Study: 24532830

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Posttrial colchicine use
Number of subjects: 90
Study: 23082123

Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment (75 mg twice a day for 5 days)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Oseltamivir treatment and prophylaxis (75 mg once a day for 10 days)
Number of subjects: 652
Study: 20111881

Group type: EXPERIMENTAL
Intervention: Nasal swab
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nasopharyngeal aspirate
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nasal swab in children with severe symptoms
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Co-infection
Number of subjects: 98
Study: 17623227

Group type: EXPERIMENTAL
Intervention: 0:10 sucrose:lactitol
Number of subjects: 75

Group type: COMPARATOR
Intervention: 10:0 sucrose:lactitol
Number of subjects: 75

Group type: COMPARATOR
Intervention: 5:5 sucrose:lactitol
Number of subjects: 75
Study: 15705721

Group type: EXPERIMENTAL
Intervention: Model-based approach for quantifying central activation failure (CAF) during a 2-min sustained maximal voluntary contraction (MVC).
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Model-based approach for quantifying peripheral fatigue (PF) during sustained MVC.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Linear interpolation method for estimating peripheral fatigue (PF).
Number of subjects: 27
Study: 12204663

Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment methodology
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Recommendations for future investigations
Number of subjects: 1026
Study: 9449256

Group type: EXPERIMENTAL
Intervention: Cefpirome (2 g twice daily)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Ceftazidime (2 g three times daily)
Number of subjects: 400
Study: 7616306

Group type: EXPERIMENTAL
Intervention: Casein protein ingestion
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Soybean protein ingestion
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fasting conditions
Number of subjects: 4
Study: 2792903

Group type: EXPERIMENTAL
Intervention: Cefoperazone plus sulbactam (antimicrobial prophylaxis)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 367853

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30017177

Group type: EXPERIMENTAL
Intervention: HDL‐apoA‐I exchange (HAE)
Number of subjects: 93
Study: 28879896

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study: 25644856

Group type: EXPERIMENTAL
Intervention: Salsalate (4 g day(-1) for 4 weeks)
Number of subjects: 24
Study: 24129009

Group type: EXPERIMENTAL
Intervention: Deductive teaching procedure
Number of subjects: 66

Group type: COMPARATOR
Intervention: Inductive teaching procedure
Number of subjects: 66
Study: 22902097

Group type: EXPERIMENTAL
Intervention: Autoinjector prefilled pen (PFP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prefilled syringe (PFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both devices (PFP and PFS)
Number of subjects: 0
Study: 19094160

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg t.i.d.) for 5 days with transdermal rotigotine patch (2 mg (24 h)(-1), 10 cm(2), total drug content 4.5 mg) applied daily for 4 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Transdermal rotigotine treatment (2 mg (24 h)(-1), 10 cm(2), total drug content 4.5 mg) applied daily for 4 days
Number of subjects: 16
Study: 17557948

Group type: COMPARATOR
Intervention: Standard public health recommendation for PA
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Breast cancer-specific PA print materials
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Step pedometer
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Combination of breast cancer-specific print materials and step pedometers
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 377
Study: 16284984

Group type: EXPERIMENTAL
Intervention: Maintenance/consolidation chemotherapy
Number of subjects: 2550
Study: 12474702

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 300 mg
Number of subjects: 192

Group type: COMPARATOR
Intervention: Pizotifen 1.5 mg
Number of subjects: 192
Study: 9809818

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metoclopramide-diphenhydramine
Number of subjects: 32
Study: 7665066

Group type: EXPERIMENTAL
Intervention: 400 mg Fe
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20,000 IE erythropoietin (rHuEPO) i.v.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2669626

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1091272

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fluspirilene
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Penfluridol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Perphenazine-enanthate
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate
Number of subjects: 5
Study: 31319234

Group type: EXPERIMENTAL
Intervention: Tunneled external ventricular drainage (T‐EVD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard external ventricular drainage (S‐EVD)
Number of subjects: 120
Study: 28562117

Group type: EXPERIMENTAL
Intervention: Omega-3 (425 mg/capsule, 2 capsules/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Soybean isoflavones (54.4 mg/tablet, 2 tablets/day)
Number of subjects: 68
Study: 25573393

Group type: EXPERIMENTAL
Intervention: Transtibial pull-out technique using 1 transtibial bone tunnel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transtibial pull-out technique using 2 transtibial bone tunnels
Number of subjects: 10
Study: 23680628

Group type: EXPERIMENTAL
Intervention: Povidone-iodine 1.0%
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Povidone-iodine 5.0%
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Povidone-iodine 10.0%
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control smear (no-surgery eye)
Number of subjects: 271
Study: 21806580

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation (8 L/min via face mask for 2 h)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Room air (control group)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation
Number of subjects: 450
Study: 19336539

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 3 mg kg(‐1) h(‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg kg(‐1) h(‐1)
Number of subjects: 12
Study: 16927064

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.2 g/kg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (isonitrogenous amino acid)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 15326084

Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 117

Group type: COMPARATOR
Intervention: High sodium diet
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Trp460Trp genotype
Number of subjects: 117
Study: 14636099

Group type: EXPERIMENTAL
Intervention: 1-minute rest interval
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 3-minute rest interval
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5-minute rest interval
Number of subjects: 17

Group type: COMPARATOR
Intervention: Different rest intervals (1, 3, 5 minutes)
Number of subjects: 17
Study: 10220009

Group type: COMPARATOR
Intervention: 5-HT uptake in platelets
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5-HT uptake sites density (Bmax)
Number of subjects: 30
Study: 7782904

Group type: EXPERIMENTAL
Intervention: Bread baked with high concentration of Na‐propionate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breads baked with sourdough, lactic acid, and Na‐propionate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breads containing lactic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: All bread products
Number of subjects: 0
Study: 2140987

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Supervised exercise therapy
Number of subjects: 36
Study: 428228

Group type: EXPERIMENTAL
Intervention: Prostaglandin vaginal suppositories
Number of subjects: 77

Group type: COMPARATOR
Intervention: Vacuum aspiration by Kahrman catheter
Number of subjects: 77
Study: 31773165

Group type: EXPERIMENTAL
Intervention: A2M (a2 Milk; exclusively containing A2 β-casein with lactose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CON (conventional milk; containing A1 and A2 β-casein and lactose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LF-CON (lactose-free conventional milk; containing A1 and A2 β-casein without lactose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NLDI subjects (irrespective of milk type)
Number of subjects: 40
Study: 31070741

Group type: EXPERIMENTAL
Intervention: UCare intervention (website + booklet)
Number of subjects: 1103

Group type: COMPARATOR
Intervention: Delayed Treatment control
Number of subjects: 1103
Study: 27798052

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18140

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18140

Group type: EXPERIMENTAL
Intervention: CRNM bleeding
Number of subjects: 18140
Study: 25823768

Group type: EXPERIMENTAL
Intervention: Transoral incisionless fundoplication (TIF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 60
Study: 23605506

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 100 μg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 200 μg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 400 μg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 600 μg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 800 μg
Number of subjects: 53
Study: 21970565

Group type: EXPERIMENTAL
Intervention: Internet-based tutorials with behavior modification strategies for nutrition, exercise, and other behaviors
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 121
Study: 19788018

Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonomalizumab
Number of subjects: 0
Study: 16625008

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 14739758

Group type: EXPERIMENTAL
Intervention: Active learning session (30 minutes of direct content delivery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic lecture (60 minutes of direct content delivery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both teaching methods
Number of subjects: 0
Study: 11704752

Group type: EXPERIMENTAL
Intervention: One-week application of terbinafine cream
Number of subjects: 43

Group type: COMPARATOR
Intervention: Four-week application of terbinafine cream
Number of subjects: 43
Study: 9163285

Group type: EXPERIMENTAL
Intervention: TIPS (n = 41)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sclerotherapy (n = 39)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 7959537

Group type: EXPERIMENTAL
Intervention: Enoximone (E) 1 to 9 micrograms/kg/min, increments of 1 microgram/kg/min every 2 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dobutamine (D) 5 to 40 micrograms/kg/min, increments of 5 micrograms/kg/min every 3 min
Number of subjects: 10
Study: 31322804

Group type: EXPERIMENTAL
Intervention: Physiogel® moisturizing creams (three test products)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30236246

Group type: EXPERIMENTAL
Intervention: LIA with ropivacaine 0.2% for postoperative analgesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: FNB with LIA of the posterior capsule
Number of subjects: 80
Study: 26554459

Group type: EXPERIMENTAL
Intervention: Monitoring (cardiorespiratory monitoring, i.e., electrocardiogram)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonmonitoring (no cardiorespiratory monitoring)
Number of subjects: 60
Study: 23897949

Group type: EXPERIMENTAL
Intervention: Feedback respiratory training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comprehensive rehabilitation therapy
Number of subjects: 22
Study: 22348643

Group type: EXPERIMENTAL
Intervention: Manual Chest Therapy (MCT)
Number of subjects: 658
Study: 19962772

Group type: EXPERIMENTAL
Intervention: High-intensity interval training for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 18427409

Group type: EXPERIMENTAL
Intervention: Experimental conditioning program (polygon training with sprint-runs and ball drills)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional conditioning (straight-line running with stretching exercises)
Number of subjects: 48
Study: 16012284

Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg/d)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Haloperidol (3‐15 mg/d)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Olanzapine (10‐20 mg/d)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Risperidone (4‐12 mg/d)
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1152
Study: 12970201

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 211

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass (CABG)
Number of subjects: 211
Study: 11789190

Group type: EXPERIMENTAL
Intervention: HANS treatment (4 treatments of 30 min each for the first 3 days, twice a day for 3 more days, and once a day for 7 days; total 15 days)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (electrodes placed at acupoints without electrical stimulation)
Number of subjects: 181
Study: 8861236

Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 28

Group type: COMPARATOR
Intervention: 27.3 mg saccharin
Number of subjects: 28
Study: 1623692

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 8 hours for 6 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6704647

Group type: EXPERIMENTAL
Intervention: Iohexol (40 ml, 350 mg I/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 0
Study: 30364933

Group type: EXPERIMENTAL
Intervention: Gene expression signatures associated with HR+ HPV and CIN1/2/3
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Gene expression signatures associated with HR HPV-free and cervical histopathology-free
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Gene expression signatures associated with HR+ HPV and cervical histopathology-free
Number of subjects: 83

Group type: COMPARATOR
Intervention: LEEP tissue gene expression
Number of subjects: 83
Study: 29126319

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 300,000 IU initially, then 1400 IU cholecalciferol and 500 mg of calcium daily for 150 days
Number of subjects: 330
Study: 26554304

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo training (active control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: ABM training
Number of subjects: 41
Study: 25540496

Group type: EXPERIMENTAL
Intervention: Self-stretching exercise for 4 weeks
Number of subjects: 81
Study: 22250851

Group type: EXPERIMENTAL
Intervention: Multisession computerized interpretation modification program (IMP), n = 23
Number of subjects: 49

Group type: COMPARATOR
Intervention: Interpretation control condition (ICC), n = 26
Number of subjects: 49
Study: 18818024

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Phase-related variability in premenstrual symptomatology
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Phase-related variability in urge to smoke
Number of subjects: 25
Study: 17095559

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg every 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Goserelin and Placebo
Number of subjects: 22
Study: 15842551

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin IV as a 1 h infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g before infusion, 5 g after infusion, 10 g at 2, 4, and 8 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4, and 8 h after drug administration)
Number of subjects: 9
Study: 12372724

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 5732

Group type: EXPERIMENTAL
Intervention: Hormonal therapies
Number of subjects: 5732

Group type: EXPERIMENTAL
Intervention: Biological therapy
Number of subjects: 5732

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5732
Study: 9653476

Group type: EXPERIMENTAL
Intervention: Rhinocort Aqua 128 micrograms
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Rhinocort Turbuhaler 140 micrograms
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138